MerTK Inhibitors Market, By Role of process (Macrophage clearance of apoptotic cells, Platelet aggregation, Cytoskeleton reorganization, Engulfment and Others), By Phase (Phase I, Phase II and Others), By End-user, (Specialty Clinics, Research & Laboratories and Others), and By Region - Market Trends, Analysis, and Forecast till 2030

• Celon Pharma SA
• Dong-A Socio Holdings Co Ltd
• Eli Lilly and Co
• Elsalys Biotech SA
• F. Hoffmann-La Roche Ltd
• HEC Pharm Co Ltd
• Hope Biosciences Inc.
• Incyte Corp
• Meryx Inc.
• Novithera SAS
• Ono Pharmaceutical Co Ltd
• Qurient Co Ltd
• Rgenix Inc.
• Signal Chem Lifesciences Corp
• TamRx LLC.

Recent News:

• According to research article by PubMed Central, Patients with primary EGFR mutations in non-small cell lung cancer (NSCLC) are now best treated with epidermal growth factor tyrosine kinase inhibitors, or EGFR-TKIs. After about a year, the patients do, however, inevitably become resistant to the EGFR-TKIs. The insensitivity of EGFR-TKI in non-small cell lung cancer is frequently caused by the activation of other receptor-mediated signaling pathways in addition to the acquisition of the EGFR T790M mutation. A poor prognosis for many tumors is linked to upregulation of the Tyro3-Axl-MERTK (TAM) family member Mer receptor tyrosine kinase (MERTK). The signaling pathways that EGFR shares, phosphoinositide 3-kinase (PI3K)/Akt and mitogen-activated protein kinase (MAPK), are triggered when particular ligands, like Gas6 and PROS1, bind to MERTK.